Pipeline and Commercial Insight: Urinary Incontinence - Lifecycle management strategies

Questions: Discounts, Updates etc.

Price: $15,200.00

Publication Date: 2007-12-26

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

The urinary Incontinence market is set to continue to grow over the next 6 years, reaching over $2.5 billion in 2012, a 68% increase from 2006. Lifecycle management strategies, novel formulations and follow-on products will drive the majority of this growth, with key brands expected to be Pfizer's Detrol LA (tolterodine) and Toviaz (fesoterodine), GSK's Vesicare (solifenacin), and Novartis' Enablex (darifenacin).


Scope

  • Analysis of patient potential, unmet needs and clinical trial design in urinary Incontinence.
  • Overview of key marketed brands, late- and early-stage pipeline drugs, and cell therapies.
  • Indication-specific sales volume and value forecasts to 2016 of marketed brands, generics, and key late-stage pipeline drugs.
  • Identification of future market events that are expected to affect urinary Incontinence drug revenues.


    • Report Highlights
    Pfizer's Detrol LA (tolterodine) will remain the market leading urinary Incontinence brand through to 2012 when it comes off patent. At this point Detrol LA will be followed by the other second generation anticholinergics, GSK's Vesicare (solifenacin), Novartis' Enablex (darifenacin) and Pfizer's chemical reformulation Toviaz (fesoterodine).

    Following the patent expiry of the key brands, Detrol LA in 2012, and Enablex/Vesicare in 2015, a novel mechanism of action is required for long-term market growth. Examples of the possible mechanisms of action include the NK-1 antagonists and the adrenergic modulators.

    Datamonitor has identified a great untapped patient base in the US stress urinary incontinence (SUI) market. A drug that could come into this market would benefit from exclusivity, being the only treatment approved for SUI in the US with a potential 28 million patient base.


    Reasons to Purchase

  • Benchmark key late-stage urinary Incontinence pipeline compounds against current market leading brands.
  • Assess region-specific (US, Japan, 5EU) sales forecasts of key late-stage pipeline drugs and marketed brands.
  • Understand unmet needs and opportunities in the urinary Incontinence urinary Incontinencemarket based on key opinion leader comments.

    • Table of Contents

    Other users found this report page using the following search terms: Urinary Incontinence Incontinence urge Incontinence stress Incontinence Detrol tolterodine fesoterodine Toviaz Vesicare solifenacin Enablex darifenacin toviaz incontinence vesicare pipeline urinary nk1 cycle life market oab

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.